Efficacy and safety of probiotic supplementation in PsA-a randomized controlled trial.

What was studied

This randomised trial tested a probiotic in psoriatic arthritis. 66 patients with moderate disease activity took part. All were on stable immune-modulating therapy. They got a probiotic with Lactobacillus and Bifidobacterium, or placebo, for 12 weeks. The main outcome was low disease activity or remission without a treatment change.

What they found

Not all 66 were in the main analysis. 13 in the probiotic group and 17 in the placebo group met the main outcome. The difference was not significant. Pain and the patients' overall rating were the score parts that improved over time. They did not differ between the groups. No differences were seen in gut permeability markers, immune cells or stool microbiome. No serious side effects related to the product were reported.

What it means for patients

The authors conclude that the probiotic did not show superiority over placebo. This holds for treatment response, the gut microbiome and permeability. They call it the first trial of its kind in this disease.

Why it is not certain yet

Only 66 patients took part, at a single centre. The main analysis used complete cases only. The odds ratio had a confidence interval from 0.13 to 1.18. The trial lasted 12 weeks.

Source

Efficacy and safety of probiotic supplementation in PsA-a randomized controlled trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.